Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126288
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez Elías, María Jesús | - |
dc.contributor.author | Arroyo, David | - |
dc.contributor.author | Diaz, Alberto | - |
dc.contributor.author | Herrero, Cristina | - |
dc.contributor.author | Martinez Dueñas, Loreto | - |
dc.contributor.author | Moreno, Ana | - |
dc.contributor.author | Hernández Quero, José | - |
dc.contributor.author | Podzamczer Palter, Daniel | - |
dc.contributor.author | Gómez Ayerbe, Cristina | - |
dc.contributor.author | Casado, José Luis | - |
dc.contributor.author | Zamora, Javier | - |
dc.contributor.author | Rivero, Antonio | - |
dc.contributor.author | Moreno Guillén, Santiago | - |
dc.contributor.author | Llibre, Josep María | - |
dc.date.accessioned | 2018-11-21T13:43:41Z | - |
dc.date.available | 2018-11-21T13:43:41Z | - |
dc.date.issued | 2014-11-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/126288 | - |
dc.description.abstract | Introduction: No controlled clinical trials had studied the role of maraviroc (MRV) in fully suppressed patients [1]. Methods and Materials: MRV-cohort is an observational, retrospective, multicentric (27 sites) large cohort study of patients starting MRV in clinical practice under different circumstances, with at least 48 weeks of follow-up. For the present analysis we selected all those patients starting with an HIV-RNAB50 copies/mL. Demographics, baseline CD4 cell count, past history of antiretroviral treatment (ART), tropism, reasons for MRV use, MRV based therapy and change/end of MRV use were assessed. Paired analysis of lipid, hepatic and kidney profile changes and univariate and multivariate analyses of HIV-RNAB50 copies/mL at 48 weeks were explored. Results: We included 247 out of 667 subjects from the entire cohort. At study entry, their median age was 47 years, 23% were women, 31% MSM, 49% had CDC category C, median CD4 counts were 468 cells/mm3 , 46% were HCV and 4.5% AgHBs. Tropism information was available in 197 (94% R5). Median length of prior ARTV was 10.7 years, with exposure to a median of three drug families. Main reasons for prescribing MRV were: toxicity 38%, inmunodiscordance 23%, simplification 19% and admission in a clinical trial 10.4%. MRV based therapies used were MRV2NRTIs 9%, MRVPI 46%, MRVPIother 40% and MRVother 5%. At 48 weeks, 23% of patients had changed or finished MRV therapy due to toxicity 2.4%, virological failure 2%, immunological failure 1.2%, simplification 3,2%, trial requirement 9.7%, medical decision 2.8%, treatment suspension 1.2% and unknown 0.4%. At 48 weeks, no significant changes were observed in lipid, hepatic or kidney profiles, and 85% of patients remained with HIV-RNAB50 copies/mL. Focusing on viral response univariate and multivariate models did not show any significant baseline variable explaining viral failure. Conclusions: In clinical practice MRV was used, mostly in R5 positive patients, with adequate efficacy and tolerance, but important number of patients changed due to non-clinical reasons. In this scenario neither reason for use of MRV nor MRVbased therapy explained viral failure. | - |
dc.format.extent | 1 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.7448/IAS.17.4.19800 | - |
dc.relation.ispartof | Journal of the International AIDS Society, 2014, vol. 17, supl. 3 | - |
dc.relation.uri | https://doi.org/10.7448/IAS.17.4.19800 | - |
dc.rights | cc by (c) Pérez Elías et al., 2014 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Antiretrovirals | - |
dc.subject.classification | Antiretroviral agents | - |
dc.subject.other | HIV (Viruses) | - |
dc.title | Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T12:36:30Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25397544 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
EliasMJP.pdf | 76.07 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License